Literature DB >> 31279691

Evolving Trends for Selected Treatments of T1a Renal Cell Carcinoma.

Johnathan Doolittle1, Joshua Piotrowski2, Keegan Zuk2, Kenneth Jacobsohn2, Peter Langenstroer2, William See2, Scott Johnson2.   

Abstract

OBJECTIVE: To evaluate contemporary trends in the management of small renal masses and how patient age has impacted practice patterns.
METHODS: Using the NCDB Participant User File (PUF) from 2002 to 2015, we identified patients with T1a renal masses. The initial treatment was categorized as radical nephrectomy (RN), partial nephrectomy (PN), ablation, or active surveillance (AS). A multinominal logistic regression model was used to identify significant factors impacting treatment.
RESULTS: We identified 75,691 patients for analysis. RN, PN, and ablation accounted for 28%, 52%, and 12%, respectively, while 8% were managed with AS. In the past decade the likelihood of undergoing PN, ablation, or surveillance compared to RN has consistently increased, independent of age, sex, race, comorbidity, tumor size, or institution. As age increased, patients were independently less likely to undergo PN and more likely to be managed with ablation or AS. Compared to patients under 40 years of age, patients between 70 and 79 were far less likely to undergo PN (RR 0.58, P< .01), and far more likely to undergo either ablation (RR 5.53, P< .01) or AS (RR 3.7, P< .01).
CONCLUSION: Trends in small renal mass management continue to evolve, with PN supplanting RN over the past decade as the predominant surgical treatment. Age significantly impacts treatment selection, particularly in older cohorts whom are much more likely to undergo ablation or AS. While the use of minimally invasive therapies has increased over the past decade, AS lags behind despite quality data supporting its use. When controlling for multiple clinical factors, PN, ablation and surveillance have consistently increased in utilization compared to RN.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31279691     DOI: 10.1016/j.urology.2019.06.029

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Are the long-term outcomes of percutaneous ablation for clinical stage T1 renal tumors similar to those of partial nephrectomy?

Authors:  Roy Mano; A Ari Hakimi
Journal:  Ann Transl Med       Date:  2019-12

2.  Percutaneous kidney ablation: a good option in selected cases.

Authors:  Samuel Weprin; Alessandro Veccia; Riccardo Autorino
Journal:  Ann Transl Med       Date:  2019-09

3.  Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care.

Authors:  Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Clin Genitourin Cancer       Date:  2020-03-20       Impact factor: 2.872

Review 4.  Is percutaneous image-guided renal tumour ablation ready for prime time?

Authors:  Roberto Luigi Cazzato; Julien Garnon; Pierre De Marini; Pierre Auloge; Guillaume Koch; Danoob Dalili; Xavier Buy; Jean Palussiere; Pramod Prabhakar Rao; Thibault Tricard; Hervé Lang; Afshin Gangi
Journal:  Br J Radiol       Date:  2020-06-22       Impact factor: 3.039

5.  The impact of a multidisciplinary small renal mass clinic on patient treatment decisions.

Authors:  Danielle Earis; Chris Wall; Nicolette Sinclair; Trustin Domes; Kunal Jana
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

Review 6.  Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices.

Authors:  Helen Wei Cui; Mark Edward Sullivan
Journal:  Transl Androl Urol       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.